Literature DB >> 24746516

β-catenin is a valuable marker for differential diagnosis of osteoblastoma and osteosarcoma.

Yang Wan1, Wendi Zhao1, Yan Jiang1, Debao Liu2, Gang Meng1, Yongping Cai3.   

Abstract

Osteoblastoma (OB) and osteosarcoma (OS) are 2 bone tumors that predominantly affect young adults. The clinical management of OS differs significantly from that of OB, and thus, accurate diagnosis of OB and OS is critical in determining appropriate treatment modality. However, in certain cases, OS significantly overlaps with OB in clinical and radiographic characteristics, and therefore, the differential diagnosis of OB and OS can be difficult, especially when biopsy material is insufficient. To date, there have been few reports on markers for differential diagnosis of OB and OS. We have previously shown that the Wnt/β-catenin pathway is inactivated in OS. In this study, we aimed to investigate whether the cellular distribution pattern of β-catenin is a potential marker for the differential diagnosis of OB and OS. Immunohistochemical staining was studied in 17 OB samples (21 biopsies; 17 primary and 4 recurrent) and 37 OS samples with complete follow-up information. Moderate-to-strong nuclear β-catenin staining was found in all OB specimens (17/17). In contrast, positive staining of β-catenin was found in the cytoplasm and/or membrane but not the nucleus in all 32 cases of nonchondroblastic OS (32/32) and the classic OS component in chondroblastic OS (5/5). The only positive nuclear β-catenin staining detected in OS biopsies was in chondroblastic OS cells (5/5). In summary, our results indicate that, in addition to conventional histopathologic evaluation, cellular distribution of β-catenin may be used as a valuable marker in the differential diagnosis of OB and OS. Nuclear β-catenin staining strongly suggests OB, whereas cytoplasmic/membranous staining of β-catenin suggests OS.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Immunohistochemistry; Osteoblastoma; Osteosarcoma; Wnt; β-catenin

Mesh:

Substances:

Year:  2014        PMID: 24746516     DOI: 10.1016/j.humpath.2014.02.022

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  9 in total

Review 1.  Wnt/β-catenin pathway in bone cancers.

Authors:  Jian Tian; Hongbo He; Guanghua Lei
Journal:  Tumour Biol       Date:  2014-08-13

2.  Hypoxia-related microRNA-210 is a diagnostic marker for discriminating osteoblastoma and osteosarcoma.

Authors:  Scott M Riester; Jorge Torres-Mora; Amel Dudakovic; Emily T Camilleri; Wei Wang; Fuhua Xu; Roman R Thaler; Jared M Evans; René Zwartbol; Inge H Briaire-de Bruijn; Avudaiappan Maran; Andrew L Folpe; Carrie Y Inwards; Peter S Rose; Thomas C Shives; Michael J Yaszemski; Franklin H Sim; David R Deyle; Annalise N Larson; Mario A Galindo; Arjen G H Cleven; Andre M Oliveira; Anne-Marie Cleton-Jansen; Judith V M G Bovée; Andre J van Wijnen
Journal:  J Orthop Res       Date:  2016-06-28       Impact factor: 3.494

3.  Usefulness of β-catenin expression in the differential diagnosis of osteosarcoma, osteoblastoma, and chondroblastoma.

Authors:  Kivilcim Eren Erdogan; Marina Pacheco; Marco Gambarotti; Giovanna Magagnoli; Marta Sbaraglia; Tommaso Frisoni; Alberto Righi; Angelo Paolo Dei Tos
Journal:  Virchows Arch       Date:  2021-01-28       Impact factor: 4.064

4.  FoxM1 is Upregulated in Osteosarcoma and Inhibition of FoxM1 Decreases Osteosarcoma Cell Proliferation, Migration, and Invasion.

Authors:  Xia Zhu; Kangyang Lu; Liyu Cao; Yong Hu; Yu Yin; Yongping Cai
Journal:  Cancer Manag Res       Date:  2020-10-09       Impact factor: 3.989

5.  Mesenchymal Tumors Can Derive from Ng2/Cspg4-Expressing Pericytes with β-Catenin Modulating the Neoplastic Phenotype.

Authors:  Shingo Sato; Yuning J Tang; Qingxia Wei; Makoto Hirata; Angela Weng; Ilkyu Han; Atsushi Okawa; Shu Takeda; Heather Whetstone; Puvindran Nadesan; David G Kirsch; Jay S Wunder; Benjamin A Alman
Journal:  Cell Rep       Date:  2016-07-14       Impact factor: 9.423

6.  SPARCL1 suppresses osteosarcoma metastasis and recruits macrophages by activation of canonical WNT/β-catenin signaling through stabilization of the WNT-receptor complex.

Authors:  S-J Zhao; Y-Q Jiang; N-W Xu; Q Li; Q Zhang; S-Y Wang; J Li; Y-H Wang; Y-L Zhang; S-H Jiang; Y-J Wang; Y-J Huang; X-X Zhang; G-A Tian; C-C Zhang; Y-Y Lv; M Dai; F Liu; R Zhang; D Zhou; Z-G Zhang
Journal:  Oncogene       Date:  2017-10-30       Impact factor: 9.867

Review 7.  Benign Bone Tumors: An Overview of What We Know Today.

Authors:  Sara De Salvo; Vito Pavone; Sebastiano Coco; Eleonora Dell'Agli; Chiara Blatti; Gianluca Testa
Journal:  J Clin Med       Date:  2022-01-28       Impact factor: 4.241

8.  Nuclear β-catenin translocation plays a key role in osteoblast differentiation of giant cell tumor of bone.

Authors:  Atsushi Kimura; Yu Toda; Yoshihiro Matsumoto; Hidetaka Yamamoto; Kenichiro Yahiro; Eijiro Shimada; Masaya Kanahori; Ryunosuke Oyama; Suguru Fukushima; Makoto Nakagawa; Nokitaka Setsu; Makoto Endo; Toshifumi Fujiwara; Tomoya Matsunobu; Yoshinao Oda; Yasuharu Nakashima
Journal:  Sci Rep       Date:  2022-08-04       Impact factor: 4.996

9.  Imaging algorithm and multimodality evaluation of spinal osteoblastoma.

Authors:  Zihuan Huang; Tingsong Fang; Zhiguang Si; Youcai Li; Lan Zhang; Chunling Zheng; Shenmei Li; Manting Su; Xiaomin Liu; Xiaodan Li; Yuankui Wu
Journal:  BMC Musculoskelet Disord       Date:  2020-04-14       Impact factor: 2.362

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.